NEUROTRANSMITTERS IN HEALTH AND DISEASE: BIOCHEMICAL PATHWAYS, SYNAPTIC DYNAMICS, AND THERAPEUTIC APPROACHES – A MEDICAL CHEMISTRY PERSPECTIVE
Keywords:
Neurotransmitters, synaptic transmission, acetylcholine, dopamine, serotonin, GABA, glutamate, neurological disorders, neurochemistry, neurotransmitter imbalance, synaptic plasticity, therapeutic approaches.Abstract
This article is based on the analysis of modern scientific publications devoted to the biochemical basis of neurotransmitter function, synaptic transmission, and the pathophysiology of neurological and psychiatric disorders. Particular attention is paid to the molecular mechanisms of neurotransmission, synaptic dysfunction in disease, and the potential application of advanced therapeutic approaches in the healthcare system of the Republic of Uzbekistan.
References
1. Kandel ER, Schwartz JH, Jessell TM, Siegelbaum SA, Hudspeth AJ. Principles of Neural Science. 6th ed. McGraw-Hill; 2021.
2. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. 8th ed. Oxford University Press; 2003.
3. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966;18(2):925–964.
4. Carlsson A. A paradigm shift in brain research. Science. 2001;294(5544):1021–1024.
5. Snyder SH, Innis RB, Ferris RM. The neurotransmitter basis of psychiatric disorders. N Engl J Med. 1989;321(13):874–884.
6. Nestler EJ, Hyman SE, Holtzman DM, Malenka RC. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. 3rd ed. McGraw-Hill; 2015.
7. Schousboe A, Waagepetersen HS. GABA: homeostatic and pharmacological aspects. Prog Brain Res. 2007;160:9–19.
8. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51(1):7–61.
9. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137–147.
10. Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016;17(8):524–532.
11. Barcia C, Carmen Gómez A, Herranz AS, Herrero MT. Nanotechnology in Parkinson's disease: recent advances. Nanomedicine. 2018;13(22):2813–2823.
12. Rao A, Sarker S, Ganesh T. Nanoparticle-based drug delivery for neurological disorders. ACS Chem Neurosci. 2021;12(15):2785–2802.
